COVID-19: Hindustan Syringes ramps up production to meet surged demand
Hindustan Syringes said it is increasing its output of auto-disable devices(which prevent re-use) from 700 million a year to one billion by 2021 to meet the expected demand.
Advertisement
Faridabad: India's biggest syringe manufacturer is ramping up production to churn out a billion units, anticipating a surge in demand as the global race to find a coronavirus vaccine heats up.
While the focus on tackling the pandemic has mostly been on the development of vaccines, experts say medical essentials to administer them are also vital.
Hindustan Syringes -- one of the world's largest makers of the item -- said it is increasing its output of auto-disable devices (which prevent re-use) from 700 million a year to one billion by 2021 to meet the expected demand.
"Even if 60 percent of the world's population is immunised, it would mean four to five billion syringes would be required," Hindustan Syringes managing director Rajiv Nath told AFP at their factory in northern Haryana state.
There are currently more than 30 candidate vaccines being tested on humans, with governments hoping to deploy one as soon as possible with the coronavirus wrecking lives and economies.
Shortages of PPE such as masks hampered early responses to the pandemic, and countries have now started building up their stockpile of syringes, vials and needles.
"We may have sufficient capacity for the first wave of vaccines which would only be administered to priority groups," Prashant Yadav, a healthcare supply chains expert at Harvard Medical School, told AFP.
"(But) when we get to a large-scale vaccination in late 2021 or 2022 and the dose demand estimates would be greater than 10 billion, that's when syringe supply starts becoming a constraint."
So far, UNICEF has ordered 140 million syringes from Hindustan for COVAX, a global initiative aimed at ensuring a more equitable distribution of vaccines to poorer nations.
Much of the world's demand for syringes is expected to be met by factories in China and India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.